Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)Β-Thalassemia Treatment with KL003 Cell Injection
Phase 1
Recruiting
- Conditions
- Transfusion-dependent Beta-Thalassemia
- Interventions
- Drug: KL003 Cell Injection Drug Product
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Kanglin Biotechnology (Hangzhou) Co., Ltd.
- Target Recruit Count
- 41
- Registration Number
- NCT06280378
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
🇨🇳Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
News
No news found